Janpreet Singh Bhandohal

Janpreet Singh Bhandohal

Auto-generated profile, based on publicly available information

Janpreet Singh Bhandohal

Department of Internal Medicine, UCLA, Kern Medical Center, Bakersfield, CA 93306, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
BMBaldeep K. Mann
Baldeep K. Mann
JBJanpreet S. Bhandohal
Janpreet S. Bhandohal
JHJungrak Hong
Jungrak Hong
This review summarizes the vast literature describing the long-term epidemiological studies with emphasis on postprandial glucose as a stronger predictor of cardiovascular complications as compared to fasting glucose and HbA1c. Many molecular studies also supported this fact by illustrating that postchallenge hyperglycemia is associated with elevated biomarkers of systemic inflammation in the plasma and thus increasing the chances of vascular damage. Large-scale studies have proved that vascular stiffness, brachial-ankle pulse-wave velocity, carotid intima thickness, and left ventricular hypertrophy have been associated with postprandial glucose as compared to fasting glucose or glycosylated hemoglobin.

1 October 2017 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
JBJanpreet Singh Bhandohal
Janpreet Singh Bhandohal
TMTaimur Mirza
Taimur Mirza

8 May 2020 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
BMBaldeep K. Mann
Baldeep K. Mann
JBJanpreet S. Bhandohal
Janpreet S. Bhandohal
MSMohammad Saeed
Mohammad Saeed
GPGerald Pekler
Gerald Pekler
Background. Cocaine use is associated with multiple cardiovascular complications including heart failure. The use of different types of beta blockers in heart failure patients with active cocaine use is still a matter of debate. In this review, our objective is to systematically review the available literature regarding the use of beta blockers in the treatment of heart failure patients with concurrent cocaine use. Methods. PubMed, EMBASE, Web of Science, and Clinical Trials.gov were searched from inception to March 2019 using the Medical Subject Headings (MeSH) terms “cocaine”, “heart failure”, “beta blocker,” and “cardiomyopathy”. Only studies containing the outcomes of heart failure patients with active cocaine use who were treated with beta blockers were included. Results. The search resulted in 2072 articles out of which 12 were finally included in the review. A total number of participants were 1994 with a median sample size of 111. Most of the studies were retrospective in nature with Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence from 3 to 5. The main primary outcomes included readmission rates, mortality, left ventricular ejection fraction (LVEF) improvement, New York Heart Association (NYHA) functional class, and major adverse cardiovascular events (MACEs). In the studies analyzed, beta blockers were found to have either a beneficial or a neutral effect on primary outcomes in heart failure patients with active cocaine use. Conclusion. The use of beta blocker therapy appears to be safe and beneficial in heart failure patients with active cocaine use, although the evidence is not robust. Furthermore, large-scale studies are required to confirm this finding.